Ischemic Stroke - Pipeline Insight, 2022

This Ischemic Stroke - Pipeline Insight, 2022 report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Ischemic Stroke Understanding

Ischemic Stroke: Overview

Ischemic strokes occur when blood supply is cut off to part of the brain. This type of stroke accounts for the majority of all strokes. The blocked blood flow in an ischemic stroke may be caused by a blood clot or by atherosclerosis, a disease which causes narrowing of the arteries over time. Ischemic strokes can be caused by a blockage anywhere along the arteries feeding the brain. Immediate emergency treatment is critical to surviving a stroke with the least amount of damage to the brain and ability to function. Ischemic strokes occur when blood supply is cut off to part of the brain by a blood clot or narrowing of the arteries. Blood clots may be caused by an irregular heartbeat such as arrhythmia, problems with the heart valve, infection of the heart muscle, hardening of the arteries, blood-clotting disorders, inflammation of the blood vessels, or a heart attack. A less common cause of ischemic stroke occurs when blood pressure becomes too low (hypotension), reducing blood flow to the brain. This usually occurs with narrowed or diseased arteries. Low blood pressure can result from a heart attack, large loss of blood or severe infection. Each of these conditions affects the flow of blood through the heart and blood vessels and increases the risk of stroke. Strokes can happen to a person of any age, including children. However, the older a person is, the higher their risk of stroke. Strokes are more common in men, but more women die from them. A family history of stroke, or a personal history of stroke or heart attack, also increase the risk of stroke. Research also has shown African-Americans are at higher risk of stroke than Caucasians. People who have symptoms of a stroke need emergency medical care. Immediate medical attention may prevent life-threatening complications, more widespread brain damage, and is critical for the recovery.

Ischemic Stroke - Pipeline Insight, 2022 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ischemic Stroke pipeline landscape is provided which includes the disease overview and Ischemic Stroke treatment guidelines. The assessment part of the report embraces, in depth Ischemic Stroke commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ischemic Stroke collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Ischemic Stroke.
• In the coming years, the Ischemic Stroke market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Ischemic Stroke R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Ischemic Stroke treatment market. Several potential therapies for Ischemic Stroke are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Ischemic Stroke market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Ischemic Stroke) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Ischemic Stroke Emerging Drugs Chapters

This segment of the Ischemic Stroke report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ischemic Stroke Emerging Drugs

MultiStem: Athersys, Inc.

The company is developing MultiStem®, a proprietary stem cell product, for the treatment of diseases and conditions in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other indications. Factors expressed by MultiStem have the potential to deliver a therapeutic benefit in several ways, such as reducing inflammation, protecting damaged or injured tissue, and enhancing the formation of new blood vessels in regions of ischemic injury. These cells exhibit a drug-like profile in that they act primarily through the production of multiple factors that regulate the immune system, protect damaged or injured cells, promote tissue repair and healing, and the cells are subsequently cleared from the body over time. Currently, it is in Phase III stage of clinical trial evaluation to treat Ischemic Stroke.

Elezanumab: Tarveda Therapeutics

Elezanumab (ABT 555) is a fully humanised monoclonal antibody, inhibiting repulsive guidance molecule a (RGMa), being developed by AbbVie, for the treatment of spinal cord injuries and acute ischemic stroke. Currently, it is in Phase II stage of clinical trial evaluation to treat acute ischemic stroke.

LT3001: Lumosa Therapeutics

LT3001, a novel molecule designed to restore occluded blood flow without causing hemorrhage, holds promise as a superior and safer therapy to expand the treatable population and improved the outcome after acute ischemic stroke.

RNS60: Revalesio Corporation

RNS60, is being developed to treat chronic neurodegenerative diseases driven by mitochondrial dysfunction, such as amyotrophic lateral sclerosis (ALS), and to improve recovery from neurological trauma, such as ischemic stroke. RNS60 uniquely activates intracellular signaling pathways that have anti-inflammatory effects and promote mitochondrial biogenesis, cell survival, and differentiation. In addition to protecting neurons and oligodendrocytes in the central nervous system, RNS60 modulates the activity of immune cells to restore cellular homeostasis throughout the body - without the undesirable side effects common to so many of today's medicines.

Ischemic Stroke: Therapeutic Assessment

This segment of the report provides insights about the different Ischemic Stroke drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Ischemic Stroke

There are approx. 50+ key companies which are developing the therapies for Ischemic Stroke. The companies which have their Ischemic Stroke drug candidates in the most advanced stage, i.e. phase III include Athersys, Inc.

Phases

This report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ischemic Stroke: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ischemic Stroke therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ischemic Stroke drugs.

Ischemic Stroke Report Insights

• Ischemic Stroke Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Ischemic Stroke Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Ischemic Stroke drugs?
• How many Ischemic Stroke drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ischemic Stroke?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ischemic Stroke therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ischemic Stroke and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Athersys, Inc.
• Tarveda Therapeutics
• Lumosa Therapeutics
• Teijin Pharma Limited
• NC Medial Research Inc
• Acticor Biotech
• Meridigen Biotech Co., Ltd.
• GrandPharma (China) Co., Ltd.
• Suzhou Yabao Pharmaceutical R&D Co., Ltd.
• Prolong Pharmaceuticals
• Nanjing Yoko Biomedical Co., Ltd.
• TrueBinding, Inc.
• GNT Pharma
• Roche
• DiaMedica Therapeutics Inc
• aptaTargets
• Bristol-Myers Squibb
• NuvOX Pharma
• Guangzhou Recomgen Biotech Co., Ltd.
• Jiangsu Simcere Pharmaceutical Co., Ltd.
• Genentech, Inc.
• Ever Supreme Bio Technology Co., Ltd.
• NoNO Inc.
• Pharming Technologies B.V.
• Biogen
• Acticor Biotech
• Avilex Pharma
• SanBio
• ZZ Biotech
• Shin Poong Pharmaceutical
• Prolong Pharmaceuticals
• Revalesio
• Stemedica Cell Technologies
• StemCyte
• Ninnion
• Algernon Pharmaceuticals

Key Players

• MultiStem
• Elezanumab
• LT3001
• AP-188
• 3K3A-APC
• NIN-S119
• RNS60
• PP 007
• SP-8203
• Glenzocimab
• SB-623
• AVLX-144
• BIIB 131
• JTR-16
• Conestat alfa
• NCS-01
• Nerinetide
• ACT017
• UMC119-06
• Tirofiban
• SY-007
• PP-007
• Edaravone
• TB006
• Neu2000
• Balovaptan
• DM 199
• ApTOLL
• BMS-986177
• NanO2
• Tenecteplase
• SIM1910-09
• UMSC01

This product will be delivered within 1-3 business days.